

**BIOGRAPHICAL SKETCH**  
**Complete for each professional associated with the project**

Name: [Last, First, Middle Initial(s), Degree(s)]  
 Scalfari Antonio, MD, PhD

Position/Title:  
 Consultant Neurologist

**Education**

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Messina	MD	1999	Research thesis: "The role of Interferons in the treatment of multiple sclerosis"
University of Messina	Neurology training	2004	Research thesis: "The quality of blinding methodology in MS clinical trials"
Imperial College London	PhD Neuro-epidemiology	2013	Research thesis: "Identification of prognostic factors predicting the long-term clinical outcome in Multiple Sclerosis"

**Research and Professional Experience**

[List in chronological order, previous employment, experience and honors]

**Research experience:**

**2003-2006** Clinical research fellowship: Oxford University, Radcliff Infirmary, Neurology department. Supervisor: Prof G. Ebers

**2007-2011** PhD in Neuro-epidemiology, funded by the Italian MS Society; Imperial

College London. Supervisor: Prof P. Muraro.

**2007**; 3 months internship at Sylvia Lawry Centre, Munich. Statistical analysis in the study of the natural history of MS. Supervisor: Dr M. Daumer.

**2013-2015** Clinical research fellowship, postdoc funded by the UK MS society. Project: The onset of the secondary progressive phase and the extreme of outcome in MS. Imperial College London. Supervisor: Prof P. Muraro.

**2017 to date** Honorary senior clinical lecturer, Imperial College London

2018 to date Member of Italian MS Society scientific committee

#### **Honors:**

**2007** Two years Research Fellowship (63.000 €): “The role of relapses affecting the long term outcome in Multiple Sclerosis” **Italian MS Society (FISM)**.

**2009** Two years Research project co-investigator (60.000 €) “Identification of early prognostic factors affecting the long-term outcome in MS: extensive analysis of the London Ontario database”. **Italian MS Society (FISM)**

**2013** Two years Postdoc Clinical Fellowship (112.768 £): “The onset of the secondary progressive phase and the extremes of outcome in Multiple Sclerosis”. **UK MS Society**.

#### **Multicenter studies:**

**2005** Co-investigator in the 16-Year Long-Term Follow-Up Study of the original Interferon-β1b trial in Multiple Sclerosis. Oxford University

**2004-2011** Reviewer of the Cochrane Multiple Sclerosis Group

**2009-2011** Co-investigator in the patient research cohort rapidly evolving Multiple Sclerosis (PRCREMS) study. Imperial College NHS trust.

**2016 to date** Co-investigator in the TONIC study: trajectories of outcome in Neurological conditions. Northwest London Healthcare Trust

#### **Clinical experience:**

**1999-2004** Resident in Neurology: University of Messina, Policlinico G. Martino

**2006-2016** Associate Specialist Neurologist. Northwest London Healthcare Trust

**2016-2017** Locum Consultant Neurologist. Northwest London Healthcare Trust

**2015-2017** Locum Consultant Neurologist; neuro-inflammatory unit, Imperial College Healthcare Trust


**2017 to date** Substantive Consultant Neurologist; Imperial College Healthcare Trust and Northwest London Healthcare Trust.

## Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

1. Alexandra Degenhardt, Sreeram V. Ramagopalan, **Antonio Scalfari** and George C. Ebers. **Clinical prognostic factors in multiple sclerosis: a natural history review**. Nature Reviews Neurology 5, 672-682 (December 2009)
2. **A.Scalfari**, A.Neuhaus, A.Degenhardt, G.P.Rice, P.A Muraro, M.Daumer and G.C.Ebers. **The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability**. Brain 2010 133: 1914-1929
3. **A.Scalfari**, R. Nicholas, O. Malik and PA Muraro. **Escalating Immunotherapies for highly active multiple sclerosis: reviewing the evidence**. CML-Multiple Sclerosis 2010; 2(3):61-73
4. **A. Scalfari**, A. Neuhaus, M. Daumer, G.C. Ebers, and P. A. Muraro. **Age and disability accumulation in multiple sclerosis**. Neurology 2011. 27;77 (13): 1246-52
5. Ebers GC, **Scalfari A**, Daumer M, Lederer C. **Combined MRI lesions and relapses as surrogate for disability in MS**. Neurology 2012;78 (17): 1367
6. **A.Scalfari**, A. Neuhaus, M. Daumer, GC DeLuca, P. A. Muraro G.C. Ebers, **Early relapses, onset of progression and late outcomes in multiple sclerosis**. JAMA Neurology 2013 Feb; 70(2):214-22
7. **A.Scalfari**, A. Knapperts V, Cutter G, Goodin DS, Ashton R and G.C. Ebers, **Mortality in patients with multiple sclerosis**. Neurology 2013 Jul 9; 81 (2): 184-92
8. **A.Scalfari**, A. Neuhaus, M. Daumer, P. A. Muraro G.C. Ebers, **Onset of secondary progressive phase and long term evolution of multiple sclerosis**. JNNP 2014 Jan;85(1):67-75.
9. **A.Scalfari**. **Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome – NO**. MS Journal 2015, Vol 21 (11), 1371-1375
10. **A. Scalfari**, C. Lederer, M. Daumer, R. Nicholas, GC. Ebers, PA. Muraro. **The relationship of age with the clinical phenotype in multiple sclerosis**. MS Journal, 2016 Nov; 22(13): 1750-1758.
11. Nandoskar A, Raffael J, **Scalfari A**, Friede T, Nicholas R. **Pharmacological approaches to the management of secondary progressive multiple sclerosis**. Drugs. 2017 May; 77(8):885-910.
12. Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, **Scalfari A**, Salanti G. **Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis**. Cochrane Database Syst Rev. 2017 Apr 25;4
13. **Scalfari A**, Romualdi C, Nicholas RS, Mattoscio M, Magliozzi R, Morra A, Monaco S, Muraro PA, Calabrese M. **The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis**. Neurology. 2018 Jun 12; 90(24)
14. C. Heesen, **A. Scalfari**, I. Galea **Prognostic information for people with MS: impossible or inevitable?** Multiple Sclerosis Journal, October 2018
15. **A. Scalfari** and P. Muraro. **Monoclonal antibody therapy and long term outcomes in multiple sclerosis-The challenge of treatment optimization**. European Neurological Review. 2018; 13(2): 78-85
16. **A. Scalfari** **MS progression is predominantly driven by age-related mechanisms-YES**. Multiple Sclerosis journal. 2019

Firma



Application. Do NOT use suffixes such as 6a, 6b...